133 related articles for article (PubMed ID: 36052036)
1. Clinical Significance of EZH2 in Acute Myeloid Leukemia.
Jiao W; Liu Y; Bao Y
Comput Intell Neurosci; 2022; 2022():8741989. PubMed ID: 36052036
[TBL] [Abstract][Full Text] [Related]
2. Higher EZH2 expression is associated with extramedullary infiltration in acute myeloid leukemia.
Zhu Q; Zhang L; Li X; Chen F; Jiang L; Yu G; Wang Z; Yin C; Jiang X; Zhong Q; Zhou H; Ding B; Wang C; Meng F
Tumour Biol; 2016 Aug; 37(8):11409-20. PubMed ID: 27000755
[TBL] [Abstract][Full Text] [Related]
3. Analysis of TET2 and EZH2 gene functions in chromosome instability in acute myeloid leukemia.
Wang J; He N; Wang R; Tian T; Han F; Zhong C; Zhang C; Hua M; Ji C; Ma D
Sci Rep; 2020 Feb; 10(1):2706. PubMed ID: 32066746
[TBL] [Abstract][Full Text] [Related]
4. EZH2 dysregulation: Potential biomarkers predicting prognosis and guiding treatment choice in acute myeloid leukaemia.
Chu MQ; Zhang TJ; Xu ZJ; Gu Y; Ma JC; Zhang W; Wen XM; Lin J; Qian J; Zhou JD
J Cell Mol Med; 2020 Jan; 24(2):1640-1649. PubMed ID: 31794134
[TBL] [Abstract][Full Text] [Related]
5. Expression of Enhancer of Zeste Homolog 2 (EZH2) Gene in Acute Myeloid Leukemia.
Hamed NAM; El Ghandour A; Abo Elwafa RA; Rezk MR; Ghallab O
Asian Pac J Cancer Prev; 2023 Jan; 24(1):81-85. PubMed ID: 36708555
[TBL] [Abstract][Full Text] [Related]
6. EZH2 mediates ATO-induced apoptosis in acute myeloid leukemia cell lines through the Wnt signaling pathway.
Zhang H; Gu H; Li L; Ren Y; Zhang L
Tumour Biol; 2016 May; 37(5):5919-23. PubMed ID: 26592252
[TBL] [Abstract][Full Text] [Related]
7. Aberrant Expression of
de Souza Fernandez T; Fonseca Alvarenga T; Almeida Antônio de Kós E; Lamim Lovatel V; Tavares RC; da Costa ES; de Souza Fernandez C; Abdelhay E
Biomed Res Int; 2019; 2019():3176565. PubMed ID: 31886200
[TBL] [Abstract][Full Text] [Related]
8. Nanoformulation of EPZ011989 Attenuates EZH2-c-Myb Epigenetic Interaction by Proteasomal Degradation in Acute Myeloid Leukemia.
Kaundal B; Srivastava AK; Dev A; Mohanbhai SJ; Karmakar S; Roy Choudhury S
Mol Pharm; 2020 Feb; 17(2):604-621. PubMed ID: 31904978
[TBL] [Abstract][Full Text] [Related]
9. HO-1 promotes resistance to an EZH2 inhibitor through the pRB-E2F pathway: correlation with the progression of myelodysplastic syndrome into acute myeloid leukemia.
He Z; Zhang S; Ma D; Fang Q; Yang L; Shen S; Chen Y; Ren L; Wang J
J Transl Med; 2019 Nov; 17(1):366. PubMed ID: 31711520
[TBL] [Abstract][Full Text] [Related]
10. Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.
Göllner S; Oellerich T; Agrawal-Singh S; Schenk T; Klein HU; Rohde C; Pabst C; Sauer T; Lerdrup M; Tavor S; Stölzel F; Herold S; Ehninger G; Köhler G; Pan KT; Urlaub H; Serve H; Dugas M; Spiekermann K; Vick B; Jeremias I; Berdel WE; Hansen K; Zelent A; Wickenhauser C; Müller LP; Thiede C; Müller-Tidow C
Nat Med; 2017 Jan; 23(1):69-78. PubMed ID: 27941792
[TBL] [Abstract][Full Text] [Related]
11. Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients.
Stomper J; Meier R; Ma T; Pfeifer D; Ihorst G; Blagitko-Dorfs N; Greve G; Zimmer D; Platzbecker U; Hagemeijer A; Schmitt-Graeff I; Lübbert M
Clin Epigenetics; 2021 Apr; 13(1):77. PubMed ID: 33845873
[TBL] [Abstract][Full Text] [Related]
12. Histone methyltransferase EZH2 epigenetically affects CCNA1 expression in acute myeloid leukemia.
Yang X; Wan M; Yu F; Wu X
Cell Signal; 2021 Nov; 87():110144. PubMed ID: 34509612
[TBL] [Abstract][Full Text] [Related]
13. A non-viral nano-delivery system targeting epigenetic methyltransferase EZH2 for precise acute myeloid leukemia therapy.
Kaundal B; Kushwaha AC; Srivastava AK; Karmakar S; Choudhury SR
J Mater Chem B; 2020 Sep; 8(37):8658-8670. PubMed ID: 32844866
[TBL] [Abstract][Full Text] [Related]
14. EZH2, new diagnosis and prognosis marker in acute myeloid leukemia patients.
Mechaal A; Menif S; Abbes S; Safra I
Adv Med Sci; 2019 Sep; 64(2):395-401. PubMed ID: 31331874
[TBL] [Abstract][Full Text] [Related]
15. EZH2 mutation in an adolescent with Weaver syndrome developing acute myeloid leukemia and secondary hemophagocytic lymphohistiocytosis.
Usemann J; Ernst T; Schäfer V; Lehmberg K; Seeger K
Am J Med Genet A; 2016 May; 170A(5):1274-7. PubMed ID: 26762561
[TBL] [Abstract][Full Text] [Related]
16. Extramedullary Infiltration in Pediatric Acute Myeloid Leukemia on Surveillance Magnetic Resonance Imaging and its Relationship With Established Risk Factors.
Kim EH; Im SA; Lee JW; Kim S; Cho B
J Pediatr Hematol Oncol; 2022 Apr; 44(3):e713-e718. PubMed ID: 35319510
[TBL] [Abstract][Full Text] [Related]
17. Quantitative proteomic analysis of EZH2 inhibition in acute myeloid leukemia reveals the targets and pathways that precede the induction of cell death.
Sandow JJ; Infusini G; Holik AZ; Brumatti G; Averink TV; Ekert PG; Webb AI
Proteomics Clin Appl; 2017 Sep; 11(9-10):. PubMed ID: 28447382
[TBL] [Abstract][Full Text] [Related]
18. Tetraspanin Family Member, CD82, Regulates Expression of EZH2 via Inactivation of p38 MAPK Signaling in Leukemia Cells.
Nishioka C; Ikezoe T; Yang J; Yokoyama A
PLoS One; 2015; 10(5):e0125017. PubMed ID: 25955299
[TBL] [Abstract][Full Text] [Related]
19. Targeting EZH2 Promotes Chemosensitivity of BCL-2 Inhibitor through Suppressing PI3K and c-KIT Signaling in Acute Myeloid Leukemia.
Yang C; Gu Y; Ge Z; Song C
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232694
[TBL] [Abstract][Full Text] [Related]
20. Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML.
Basheer F; Giotopoulos G; Meduri E; Yun H; Mazan M; Sasca D; Gallipoli P; Marando L; Gozdecka M; Asby R; Sheppard O; Dudek M; Bullinger L; Döhner H; Dillon R; Freeman S; Ottmann O; Burnett A; Russell N; Papaemmanuil E; Hills R; Campbell P; Vassiliou GS; Huntly BJP
J Exp Med; 2019 Apr; 216(4):966-981. PubMed ID: 30890554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
